Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03468218 · OUTCOME

Progression Free Survival (PFS)

Pembrolizumab & Cabozantinib in Patients With Head and Neck Squamous Cell Cancer · Source last updated 2026-01-23

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
percentage of participants
Interval / dispersion
95% Confidence Interval
Time frame
Duration from date of treatment start to the date of objectively documented progression or death due to any cause, whichever status is recorded first, assessed up to 2 years

What was measured

The median PFS will be estimated by Kaplan-Meier method along with 95% confidence interval. The biomarker association with PFS will be assessed by the Kaplan-Meier method, log-rank test, and Cox model.

Groups in this outcome

Treatment (Pembrolizumab, Cabozantinib)

Patients receive pembrolizumab IV over 30 minutes on day 1 and cabozantinib PO QD on days 1-21. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Cabozantinib: Given PO Pembrolizumab: Given IV

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Treatment (Pembrolizumab, Cabozantinib)36

Reported measurements

Source class 1
Values in percentage of participants · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Treatment (Pembrolizumab, Cabozantinib)54Not reported31.572Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        31.5
        upper Limit
        72
        value
        54
denoms
  1. counts
    1. group Id
      OG000
      value
      36
    units
    Participants
description
The median PFS will be estimated by Kaplan-Meier method along with 95% confidence interval. The biomarker association with PFS will be assessed by the Kaplan-Meier method, log-rank test, and Cox model.
dispersion Type
95% Confidence Interval
groups
  1. description
    Patients receive pembrolizumab IV over 30 minutes on day 1 and cabozantinib PO QD on days 1-21. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Cabozantinib: Given PO Pembrolizumab: Given IV
    id
    OG000
    title
    Treatment (Pembrolizumab, Cabozantinib)
param Type
NUMBER
reporting Status
POSTED
time Frame
Duration from date of treatment start to the date of objectively documented progression or death due to any cause, whichever status is recorded first, assessed up to 2 years
title
Progression Free Survival (PFS)
type
SECONDARY
unit Of Measure
percentage of participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice